ATE253941T1 - Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden - Google Patents

Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden

Info

Publication number
ATE253941T1
ATE253941T1 AT98928901T AT98928901T ATE253941T1 AT E253941 T1 ATE253941 T1 AT E253941T1 AT 98928901 T AT98928901 T AT 98928901T AT 98928901 T AT98928901 T AT 98928901T AT E253941 T1 ATE253941 T1 AT E253941T1
Authority
AT
Austria
Prior art keywords
active ingredients
decomposed
composition
water
storage stability
Prior art date
Application number
AT98928901T
Other languages
English (en)
Inventor
Stella J Valentino
Original Assignee
Cydex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Inc filed Critical Cydex Inc
Application granted granted Critical
Publication of ATE253941T1 publication Critical patent/ATE253941T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98928901T 1997-06-13 1998-06-12 Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden ATE253941T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5090997P 1997-06-13 1997-06-13
PCT/US1998/011596 WO1998056422A1 (en) 1997-06-13 1998-06-12 Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof

Publications (1)

Publication Number Publication Date
ATE253941T1 true ATE253941T1 (de) 2003-11-15

Family

ID=21968241

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98928901T ATE253941T1 (de) 1997-06-13 1998-06-12 Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden

Country Status (9)

Country Link
US (1) US6133248A (de)
EP (1) EP0986403B1 (de)
JP (1) JP4439596B2 (de)
AT (1) ATE253941T1 (de)
AU (1) AU750207B2 (de)
DE (1) DE69819721T2 (de)
ES (1) ES2210769T3 (de)
PT (1) PT986403E (de)
WO (1) WO1998056422A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030312A1 (es) * 2000-08-03 2003-08-20 Antares Pharma Ipl Ag Composicion novedosa para la administracion transdermica y/o transmucosica de compuestos activos, que asegura adecuados niveles terapeuticos
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
EP1414498A2 (de) * 2001-06-29 2004-05-06 Maxygen Aps Stabilisierte formulierungen für interferon mit sulfoalkyl ether cyclodextrinen
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
JP4727923B2 (ja) * 2001-12-20 2011-07-20 シェーリング コーポレイション Ｓｙｎ３組成物およびその方法
BR0307898A (pt) * 2002-02-22 2004-12-07 Pharmacia Corp Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
AU2003213210A1 (en) * 2002-02-22 2003-09-09 Pharmacia Corporation Ophthalmic formulation with gum system
NZ546106A (en) 2003-10-10 2008-10-31 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
CN103554222A (zh) 2004-04-15 2014-02-05 欧尼斯治疗公司 用于抑制蛋白酶体酶的化合物
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
ES2510840T3 (es) * 2004-05-10 2014-10-21 Onyx Therapeutics, Inc. Compuestos para la inhibición enzimática del proteosoma
DE602005026556D1 (de) * 2004-12-07 2011-04-07 Proteolix Inc Zusammensetzung zur proteasomhemmung
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
JP5436860B2 (ja) * 2005-11-09 2014-03-05 オニキス セラピューティクス， インク． 酵素阻害のための化合物
BRPI0618653A2 (pt) * 2005-11-15 2011-09-06 Baxter Int composições compreendendo inibidores da lipoxigenase e ciclodextrina
US20070135586A1 (en) * 2005-12-09 2007-06-14 Shreyas Chakravarti Polyamide blend compositions formed article and process thereof
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
MY183014A (en) * 2006-06-19 2021-02-05 Onyx Therapeutics Inc Compounds for enzyme inhibition
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
PT2061458E (pt) * 2006-09-15 2015-03-11 Univ Minnesota Composições de topiramato e métodos para a sua utilização
CA2685331C (en) 2007-04-27 2016-07-05 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
WO2009018326A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
KR20150131405A (ko) * 2007-10-04 2015-11-24 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CA2762321A1 (en) * 2008-05-19 2009-11-26 Texcontor Etablissement Fosphenytoin composition
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
KR20190071006A (ko) 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
MX388477B (es) 2009-05-29 2025-03-12 Cydex Pharmaceuticals Inc Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de fabricación y uso de las mismas.
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
EP2445502B2 (de) 2009-06-25 2022-09-28 Alkermes Pharma Ireland Limited Heterozyklische verbindungen zur behandlung von neurologischen und psychologischen erkrankungen
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
AU2011245630B2 (en) 2010-04-07 2014-07-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
DE102011011028A1 (de) * 2011-02-11 2012-08-16 Ditter Plastic Gmbh + Co. Kg Frontplatte mit darin eingespritztem Lichtleiter
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
CA2847842C (en) 2011-09-18 2019-12-31 Euro-Celtique S.A. Pharmaceutical compositions
EP2790734B1 (de) 2011-12-15 2019-02-20 Alkermes Pharma Ireland Limited Prodrugs von sekundären aminverbindungen
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
EP4083075A1 (de) 2012-02-15 2022-11-02 CyDex Pharmaceuticals, Inc. Verfahren zur herstellung von cyclodextrinderivaten
WO2013130666A1 (en) 2012-02-28 2013-09-06 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
JP6471089B2 (ja) 2012-03-19 2019-02-13 アルカームス ファーマ アイルランド リミテッド 脂肪酸エステルを含む医薬組成物
EP2827867B1 (de) 2012-03-19 2019-11-06 Alkermes Pharma Ireland Limited Pharmazeutische zusammensetzungen mit glycerinestern
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
EP2897592B1 (de) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmazeutische zusammensetzungen mit verbesserter lagerstabilität
MX360192B (es) 2012-10-22 2018-10-24 Cydex Pharmaceuticals Inc Composiciones de ciclodextrinas alquiladas y procesos para preparar y usar las mismas.
CN110368360A (zh) 2014-03-20 2019-10-25 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
JP6914188B2 (ja) 2014-08-22 2021-08-04 サイデックス・ファーマシューティカルズ・インコーポレイテッド 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略
US12377076B2 (en) 2018-12-18 2025-08-05 Purdue Pharma L.P. Compounds for treating lymphoma or a T-cell malignant disease
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CN110279664B (zh) * 2019-07-30 2021-09-03 四川农业大学 一种氟苯尼考包合物冻干粉针剂及其制备方法
WO2021026310A1 (en) 2019-08-06 2021-02-11 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
JP2023551145A (ja) 2020-11-18 2023-12-07 ベクソン バイオメディカル，インク． 医薬化合物の錯化剤塩製剤
CN114588116B (zh) * 2020-12-04 2024-03-15 四川科瑞德制药股份有限公司 磷苯妥英钠固体组合物、冻干方法、及其用途
KR20230096074A (ko) * 2020-12-04 2023-06-29 시추안 크레딧 파마슈티컬스 컴퍼니 리미티드 포스페니토인 나트륨 고체 조성물, 동결건조 방법 및 포스페니토인 나트륨 고체 조성물의 사용
EP4525916A1 (de) * 2022-05-18 2025-03-26 Bexson Biomedical, Inc. Komplexbildnersalzformulierungen von pharmazeutischen verbindungen bei niedrigen stöchiometrischen verhältnissen
WO2024231293A1 (en) 2023-05-05 2024-11-14 Euro-Celtique S.A. Combinations for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
US4616008A (en) * 1984-05-02 1986-10-07 Takeda Chemical Industries, Ltd. Antibacterial solid composition for oral administration
JPS61165322A (ja) * 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
US4925860A (en) * 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
DE3938227C1 (en) * 1989-11-17 1991-05-02 Dolorgiet Gmbh & Co Kg, 5205 St Augustin, De Oral antiinflammatory and analgetic pharmaceutical compsn. - comprises magnesium ibuprofen dissolved in mixt. of water, propane-1,2-diol and glycerol
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
DE839528T1 (de) * 1996-10-29 1998-10-22 Staroil Ltd Mundlösliche Zusammensetzungen die N-Acetylcystein und Cyclodextrin enthalten

Also Published As

Publication number Publication date
US6133248A (en) 2000-10-17
PT986403E (pt) 2004-04-30
JP2002511861A (ja) 2002-04-16
EP0986403A1 (de) 2000-03-22
AU750207B2 (en) 2002-07-11
DE69819721T2 (de) 2004-09-23
EP0986403B1 (de) 2003-11-12
DE69819721D1 (de) 2003-12-18
AU8059198A (en) 1998-12-30
ES2210769T3 (es) 2004-07-01
JP4439596B2 (ja) 2010-03-24
WO1998056422A1 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
ATE253941T1 (de) Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden
DE69812343D1 (de) Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff
DE69915733D1 (de) Kosmetische oder pharmazeutische Zusammensetzung in Form eines Feststoffs, welche verformt werden kann
DE69942154D1 (de) Medikamenthaltige zusammensetzung in aerosolform
EP1283054A4 (de) Medikamente zur behandlung von komplikationen des diabetes und neuropathien, und verwendung davon
AU2003304237A1 (en) Gel-stabilized nanoparticulate active agent compositions
ATE226815T1 (de) Herstellung von arzneimitteln
DE3482041D1 (de) Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta-cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten.
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
DE69418468D1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
GR3036211T3 (en) Taxane class derivative based pharmaceutical compositions
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
BG101141A (en) Fungicidal composition and method for fungous disease control
ATE254922T1 (de) Pharmazeutische zusammensetzungen mit antimikrobieller wirkung
ATE84045T1 (de) Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen.
TW345496B (en) Skin care composition containing retinol
BR9809057A (pt) Composições antitussìgenas
EP0931545A3 (de) Droloxifen pharmazeutische Zusammenstellung
KR940011014A (ko) 안정화된 수퍼옥사이드 디스뮤타아제(sod) 조성물
TW372193B (en) Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient
ATE363909T1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
ATE173624T1 (de) Synergistische pharmazeutische zusammensetungen, die triamcinolonacetonid und halcinonid enthalten
BR9608721A (pt) Composição farmacêutica, e, processo para tratar inflamação
KR890001556A (ko) 약제학적 조성물
RU94017429A (ru) Мазь "синафлан - цд"

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0986403

Country of ref document: EP

EEFA Change of the company name